WilmerHale Advises Thermo Fisher Scientific in $1.14B Sale of Anatomical Pathology Business

WilmerHale Advises Thermo Fisher Scientific in $1.14B Sale of Anatomical Pathology Business

Client News

Related Solutions

WilmerHale’s corporate lawyers have a long history of experience with cross-border deals involving mergers and acquisitions, public offerings and capital markets, venture capital, joint ventures and other transactions.
Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

On January 28, 2019, Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it signed a definitive agreement to sell its Anatomical Pathology business to PHC Holdings Corporation, a global innovator in healthcare solutions, for approximately $1.14 billion in cash. Thermo Fisher anticipates closing the transaction in the second quarter of 2019, subject to customary closing conditions and applicable regulatory approvals. 

The WilmerHale team representing Thermo Fisher on the deal was led by Hal Leibowitz, Joe Conahan and Andrew Langworthy and included Robert Burke, Ciara Baker, John Sigel, Justin Ochs, Amy Null, Scott Kilgore, Ashwin Gokhale, Christian Crones, Lester Ross and Jasmine Haddad. 

Read the press release announcing the signing of this agreement.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel